At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,312 enrolled
Drug / intervention
Esomeprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.
In Brief
A Phase 3 clinical trial evaluating Esomeprazole for Gastrointestinal Hemorrhage. Completed, enrolled 1,312 participants across 78 sites in 16 countries.
Detailed Summary
This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Hemorrhage
CountriesAustria, Denmark, Finland, France, Germany, Greece, Hong Kong, Netherlands, Norway, Romania, Russia, South Africa, Spain, Sweden, Turkey (Türkiye), United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedNov 2005
Primary CompletionDec 2007
TodayJul 2026
First PostedNov 11, 2005
Enrollment StartOct 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 20.6 years ago
Interventions
Esomeprazoledrug